Infants with the most severe forms of bronchopulmonary dysplasia (BPD) may require long-term invasive positive pressure ventilation for survival, therefore necessitating tracheostomy. Although life-saving, tracheostomy has also been associated with high mortality, postoperative complications, high readmission rates, neurodevelopmental impairment, and significant caregiver burden, making it a highly complex and challenging decision. However, for some infants tracheostomy may be necessary for survival and the only way to facilitate a timely and safe transition home. The specific indications for tracheostomy and the timing of the procedure in infants with severe BPD are currently unknown. Hence, centers and clinicians display broad variations in practice with regard to tracheostomy, which presents barriers to designing evidence-generating studies and establishing a consensus approach. As the incidence of severe BPD continues to rise, the question remains, how do we decide on tracheostomy to provide optimal outcomes for these patients?
Hypoglossia is a rare congenital anomaly resulting in a small rudimentary tongue. It is classified under the oromandibular-limb hypogenesis syndrome and can be found in isolation (Type IA) but is more often associated with other congenital disorders, such as limb defects. Isolated hypoglossia cases are rare, and while feeding disorders are common, in some cases, neonatal airway obstruction is the most problematic. In the present report, we discuss two cases of newborns presenting with hypoglossia without limb deformities or visceral anomalies: one new case and a 10-year update of a previously reported case. These two cases highlight the variability in presenting symptoms and the challenges in diagnosis and management of a rare clinical entity. We focus on the discussion of early diagnosis, multidisciplinary management, and shared decision-making, with emphasis on the current therapeutic strategies available to the clinician and their limitations during the neonatal period. Early surgical multivector mandibular distraction osteogenesis can be proposed with minimal short- and long-term morbidity, pending a consistent follow-up. This clinical entity will require multidisciplinary team care into adult years.
1 July 2025 in International Journal of Pediatric Otorhinolaryngology
Objective(s): Proper tracheostomy tube position is crucial in pediatric patients to reduce decannulation and ensure adequate ventilation. Little research exists on optimal tracheostomy length and its impact on ventilation. This study aimed to examine changes in FiO2, with a secondary focus on PEEP, albuterol and bagging associated with increasing tracheostomy length. This is an IRB-approved single-institution case series retrospective review of patients under 2 who received a tracheostomy upsize between 2018 and 2022. Data collected includes demographics, comorbidities, tracheostomy details, and FiO2 prior and following upsize. Interrupted time-series segmented linear models assessed differences in FiO2 and PEEP. Albuterol administration and bagging events were included as binary measures. Albuterol use is summarized using percentages and bagging visualized on a bar chart. A total of 118 patients underwent tracheostomy, and 71 (52 % male, 48 % female) underwent at least one upsizing at a median of 1.55 months post initial placement. These 71 patients received the first upsize, 32 patients received a second upsize, and 11 patients received a third upsize. FiO2 levels were not found to be different after upsizes 1 and 2 (beta:0.43(95 %CI: 1.7,2.6); beta:0.85(95 %CI: 1.9,3.6)). FiO2 was higher after upsize 3 (beta:5.2(95 %CI: 1.7,8.6)). Analysis of PEEP, albuterol, and bagging was limited due inconsistent documentation. This study provides insight into the changing respiratory parameters, mainly FiO2, associated with tracheostomy upsize. The higher FiO2 requirements after the third upsize indicates this subgroup of patients have greater respiratory support needs and further increasing the tracheostomy length may be of limited benefit.